医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

The Belmont® Rapid Infuser Expands Distribution to Japan

2014年01月28日 AM06:40
このエントリーをはてなブックマークに追加


 

BILLERICA, Mass.

Belmont Instrument Corporation announced this week that the Belmont® Rapid Infuser has been approved for use in Japan and will begin distributing the device through its partnership with Mediconovus Ltd. of Yokohama. The Belmont® Rapid Infuser is recognized as the standard of care for the treatment of massive blood loss in hospitals throughout the world.

The Belmont® Rapid Infuser, manufactured at the Belmont Instrument facility in Billerica, MA, combines advanced fluid heating and control technology to infuse large amounts of vital fluids warmed to physiological temperature at flow rates up to 1 L/min. The Rapid Infuser is equipped with multiple air, temperature, and pressure sensors to protect the patient, and to ensure the safety and efficacy of the infusion process.

This life-saving device has been used in over 420,000 procedures in more than 50 countries. There are currently more than 3,500 systems in use throughout the world. The Belmont® Rapid Infuser has been used extensively by the U.S. military and by many foreign medical teams in Iraq and Afghanistan and has been credited with helping to save the lives of hundreds of soldiers and civilians.

Belmont Instrument Corporation has developed sophisticated and reliable devices for massive transfusion, temperature management, and cardiac assist since its founding in 1980.

CONTACT

Belmont Instrument Corporation
Lisa Kelly, 978-663-0212 ext. 121
lkelly@belmontinstrument.com
www.belmontinstrument.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • スミス・ディテクションのBioFlashが空中のCOVID-19を検出可能であることを実証
  • Korean Pet Care Robot PEDDY Gains Popularity to Relieve Pets’ Depression During COVID-19
  • コロナ禍で生じたうつ病をいやす韓国産ペットケアロボット「ペディ」が人気
  • Dr. Reddy’s Laboratories announces the launch of Fluphenazine Hydrochloride Tablets, USP in the U.S. Market
  • Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists